A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer.
Stereotactic body radiation therapy (SBRT) is a new treatment modality. To confirm the safety and efficacy, the Radiation Therapy Study Group of the Japan Clinical Oncology Group (JCOG) has started a phase II study of SBRT for stage IA non-small cell lung cancer (JCOG 0403). This study is ongoing with a strict quality control and quality assurance program, and the results will indicate whether a future phase III trial comparing SBRT with surgery is warranted. In addition, international collaboration will be critical to establish the role of SBRT in the treatment of lung cancer.
Hiraoka
Masahiro
M
Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Graduate School of Medicine, Shogoin Kawaharacho, Sakyo-ku, Kyoto, Japan. hiraok@kuhp.kyoto-u.ac.jp
Ishikura
Satoshi
S
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011786:Quality Control; D011829:Radiation Dosage; D016634:Radiosurgery / Q000592:standards